Q4 EARNINGS: CareFusion finishes 2014 with a flourish
This article was originally published in Clinica
CareFusion ended the year strongly, with 24% revenue growth during its fourth quarter. Both of its main business units performed well, with medical systems growing 20% year-on-year and procedural solutions expanding 32%. Q4 net income also grew to $140m, or $0.67 per diluted share, from $109m, or $0.49 per diluted share during the same period last year.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.